Clinical Trial Reports That Re-Treatment With A Single TearCare(R) Treatment Continues To Provide Relief For Patients With Dry Eye Disease

Study confirms significant results through 12 months of treatment with first personalized open-eye experience MENLO PARK, Calif., Feb. 12, 2019 -- (Healthcare Sales & Marketing Network) -- A new, single center, prospective clinical study published in t... Devices, Ophthalmology Sight Sciences, TearCare, dry eye, meibomian gland

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2044751

Source: HSMN NewsFeed - February 12, 2019 Category: Pharmaceuticals Source Type: news